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Segment.specific localization of intestinal.type alkaline phosphatase in
human kidney. Specific monoclonal antibodies raised against human
intestinal and human tissue-unspecific alkaline phosphatase (AP) were
developed and were used to study the expression of these two isoen-
zymes in human renal tissue and their release into urine. Approximately
25% of the total AP content of renal tissue at the transition between
cortex and medulla was of the intestinal type: the remainder was of the
tissue-unspecific type (liver, bone, kidney AP). Immunoperoxidase
staining using specific monoclonal antibodies against liver and intestinal
AP revealed that the tissue-unspecific AP isoenzyme is present through-
out the different segments of the proximal tubule, whereas intestinal-
type AP is found exclusively in tubuloepithelial cells of the S3-segment
of the proximal tubule. The intestinal-type enzyme obtained from the
kidney had a similar heat stability and Km value, and similar immuno-
logic and inhibitory (L-p-bromotetramisole: L-phenylalanine) charac-
teristics compared to adult intestinal and fetal intestinal AP. Its elec-
trophoretic mobility in agarose gel was intermediate between that of
adult intestinal and fetal intestinal AP: after neuraminidase treatment it
became indistinguishable from the adult intestinal isoenzyme. The
intestinal-type AP found in the urine was not sensitive to neuraminidase
and had a molecular weight significantly lower than the urinary tissue-
unspecific AP isoenzyme. in conclusion, intestinal AP in the kidney is
a specific marker for the brush border of the S3 segment of the proximal
tubule, and this finding opens new perspectives in the cell biology of
this particular part of the nephron.
The kidney is a complex organ consisting in several microan-
atomical structures, each having distinct functional tasks. To
relate these functions and corresponding anatomical structures,
the availability of markers specific for each nephron segment
would be of great interest [1].
Renal proximal tubules and particularly the S3 segment are
the predilected target for the possible toxic effects of chemical
substances and drugs [2]. Consequently, the diagnostic poten-
tial of any assay for the early detection of tubular injury
depends primarily on its specificity for a particular segment or
cell type.
At least ten urinary enzymes have been, and still are, used to
detect alterations or damage of tubular segments of the neph-
ron, but none of them have sufficient segment specificity.
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Moreover, these enzymes suffer from instability in urine. [1, 3,
4]
One of these enzymes is alkaline phosphatase (AP; ortho-
phosphoric-mono-ester phosphohydrolase; EC 3.1.3.1.), a mul-
tienzyme family encoded by at least four gene loci, that is
placental, testicular, intestinal and liver, bone, kidney AP also
called tissue-unspecific AP [5]. The classical kidney isoenzyme
of AP, localized on the brush border of proximal tubule cells,
shares several properties with the liver and bone isoenzymes.
The differences in electrophoretic mobilities of kidney, liver
and bone AP are due to variation in carbohydrate side chains
161.
Although intestinal AP was originally considered to be
uniquely present in the intestine, polyclonal anti-intestinal AP
antibodies have been found to cross-react with a fraction of
kidney AP [7—91 also present in urine [101.
In the present study monoclonal antibody-based enzyme-
immunoassays were used for the specific detection of intestinal
AP and tissue-unspecific AP in human renal tissue extracts and
urine samples. In urine, both the enzymatically active fraction
and the immunoreactive fraction of intestinal AP was mea-
sured. In addition, the biochemical characteristics of intestinal-
type AP isolated from kidney extracts were compared with
those of fetal and adult intestinal AP. Histochemical staining in
the presence or absence of L-p-bromotetramisole and immuno-
histochemical staining of kidney sections with a specific mono-
clonal antibody for intestinal AP and for tissue-unspecific AP
was carried out to identify the renal cells that express intestinal-
type and tissue-unspecific AP.
Methods
Purification of alkaline phosphatases
For the purification of fetal intestinal AP, a pool of human
meconium (N = 15) was homogenized with an ultraturax (IKA
Werk, Staufen, FRG) in 50 mrt Tris-HCI buffer, pH 7.6,
containing I mM MgCI2, 50 sM ZnCI2, 200,000 lU/liter aproti-
nine (Bayer, Leverkusen, FRG). 0.1% Triton X-100 and 300mM
NaCI (homogenizing buffer). A first purification step consisted
in the batch-wise addition of DE-52 cellulose (Whatman Inter-
national Ltd. Maidstone, UK), equilibrated in homogenizing
buffer. Under these conditions intestinal AP did not bind to the
gel, while a large amount of viscous contaminants was bound.
Unbound material was extracted twice with n-butanol (2/I,
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vollvol), and the aqueous phases were further purified by
Q-Sepharose anion exchange chromatography (gradient elution
with 0 to 300 mi NaCI in Tris-HCI buffer, pH 7.6) and Reactive
Yellow 13-Sepharose-4B (Hoechst, Marburg, FRG) affinity
chromatography [11] (gradient elution with 0 to 50 m sodium
phosphate buffer, pH 8.4). After each purification step, protein
determinations were performed according to Redingbourgh and
Campbell [12] with human albumin (5.0 g/dl) and globulin (3.0
g/dl) as protein standards (Sigma Chemical Co., St. Louis,
Missouri, USA). This purification procedure resulted in an
overall recovery of 40% of the original AP activity: the final
specific activity of fetal intestinal AP was approximately 3000
LU/mg.
Adult intestinal AP was prepared from a pool of human
jejunal microvilli obtained at autopsy (within 30 mm after
death), and was purified as described for fetal intestinal AP,
except for the omission of the batch-wise adsorption step on
DE-52 cellulose.
Kidney AP was extracted twice with n-butanol (2/I, vol/vol)
from normal renal cortical tissue obtained at autopsy, and was
further purified by subsequent Q-Sepharose anion exchange
chromatography (gradient elution with 0 to 300 mt NaCI in
Tris-HCI buffer, pH 7.6), Zn-chelation chromatography (gradi-
ent elution with 0 to 20 mt Imidazole (Janssen Chimica,
Beerse, Belgium) in Tris-HCI buffer, pH 7.6, containing 300 mM
NaCI) and wheat germ lectin chromatography (gradient elution
with 0 to 5% N-acetyl-glucosamine in Tris-HCI buffer. pH 7.6,
containing 300 mri NaCI). Intestinal-type AP from kidney was
separated from tissue-unspecific AP by Reactive Yellow 13-
Sepharose-4B affinity chromatography [II).
Liver AP was prepared from human autopsy liver by extrac-
tion with n-butanol (2/1, vol/vol) and was further purified as
described for kidney AP.
Placental AP was extracted twice with n-butanol (2/1, vol/vol)
from fresh full-term placenta, and was further purified by anion
exchange chromatography (gradient elution with 0 to 200 mri
NaCI in Tris-HCI buffer, pH 7.6) and by HPLC gel filtration on
a TSK G3000SW column (0.66 x 33 cm; Toyo Soda Manufac-
turing Co., Ltd., Tokyo, Japan) in saline.
Bone AP was obtained from the serum of a patient with
Paget's disease.
Monoclonal antibody production
Six-week-old female Balb/c mice (Center for Laboratory
Animals, Catholic University, Leuven, Belgium) were injected
intraperitoneally and intradermally with an emulsion of 100 .d
complete Freund adjuvant (Gibco, Paisley, Scotland, UK) and
100 l purified AP solution in saline (1 mg/mI). Booster injec-
tions were given at two-week intervals with the same amount of
antigen in incomplete adjuvant. At days —3, —2 and —I before
fusion, 75 g AP was injected into the tail vein. Spleen
lymphocytes were fused with Sp2/0 myeloma cells (Flow Lab-
oratories, McLean, Virginia, USA) in a ratio of I myeloma cell
to 2 spleen cells with polyethylene glycol 4000 (Merck, Darm-
stadt, FRG) as the fusion agent. Cells were diluted to 5 x l0
cells/mI and were plated at I mI/well in a 24-well plate [13].
Anti-AP antibody producing hybridomas were detected in an
enzyme antigen immunoassay (EALA; vide infra) and mono-
clonality was achieved by repetitive subcloning using the lim-
iting dilution technique [14].
Antibody specificity was determined against a panel of dif-
ferent AP isoenzymes (adult and fetal intestinal AP, placental
AP, and tissue-unspecific AP of liver, bone and kidney origin),
in the EAIA-system and also by starch gel electrophoresis
according to Poulik [15]. after incubation of the different
isoenzymes with an excess of antibody. Determination of the
immunoglobulin-class was carried out in the EAIA-system by
using class-specific polyclonal rabbit anti-mouse antisera (Or-
ganon Teknika NV, Turnhout, Belgium).
Alkaline phosphatase activity determination
One unit of activity is defined as the quantity of enzyme that
catalyzes the hydrolysis of 1 mol of p-nitrophenylphosphate
(Janssen Chimica, Beerse, Belgium) per minute at 30°C. AP
activity was assayed at pH 10.4 by using 16 mtvi p-nitrophe-
nylphosphate, 350 mri 2-amino-2-methyl-l-propanol, 2 mM
Mg-acetate, I mM ZnSO4 and 2 mt hydroxyl-EDTA (substrate
solution) according to the instructions of the IFCC [16].
Extraction of alkaline phosphatase from renal tissue samples
Specimens of 200 mg renal tissue, taken from the upper
cortex, the outer stripe of the outer medulla and the inner
medulla were obtained from macroscopically normal kidneys
from patients with normal renal function and without protein-
uria, either at autopsy, or at the moment of surgery for patients
with renal cancer partly involving one kidney. Microscopic
examination of a Dubosq Brazil-fixed adjacent sample of the
specimens taken at nephrectomy was performed to ascertain
that AP was indeed extracted from non-tumoral renal tissue.
The specimens were homogenized with an ultraturax in 50 mM
Tris-HCI buffer, pH 7.6, containing 1 mi MgCI2, 50 LM ZnCl2,
200,000 lU/liter aprotinine and 1 mt benzamidine. These
homogenates were extracted twice with n-butanol (2/I, vol/vol),
the aqueous phases were pooled and were dialyzed against the
same buffer containing 0.1% Triton X-100.
I,nmuno-enzymatic determination of intestinal-type and
tissue-unspecific alkaline phosphatase content in kidney
extracts (EAJA)
Monoclonal antibody "lAP 250", specific for fetal and adult
intestinal AP, was used to measure intestinal AP in kidney
extracts in an EAIA-system. Microtiter plate wells (immuno-
plate I, Nunc, Roskilde, Denmark) were coated for three hours
at 37°C with 200 1.d rabbit anti-mouse immunoglobulin (Dako-
patts, Glostrup, Denmark) diluted 1:1000 with 10 m Tris-HCI
buffer, pH 8.5, containing 10 mti NaCI and 10 mM NaN3. The
remaining protein adsorption sites on the solid support were
blocked with 250 iI PBS containing 0.1% casein (Merck,
Darmstadt, FRG). Antibody IAP 250" (200 I of spent hybrid-
oma medium, diluted in blocking solution at a final antibody
concentration of 1.0 to 0.5 pg/mI) was then added to the wells
and plates were incubated for three hours at 37°C. Subse-
quently, 200 .d of intestinal AP standards or dilutions of kidney
extracts were added for an overnight incubation at 4°C. AP
activity was revealed with 200 l substrate solution (vide
supra), and the absorption was followed at 405 nm in a
multi-well reader (EAR 400, SLT-labinstruments, Grodig, Aus-
tria). After each incubation step the wells were washed three
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times with PBS containing 0.05% Tween 20 (ICI Americas Inc.,
Wilmington, Delaware, USA; 300 .d/well).
Tissue-unspecific AP was determined in an analogous EAIA-
system using a mixture of three of our monoclonal antibodies,
"LAP 23#" of hybridomas "LAP 232", "LAP 234" and "LAP
235", all specific for tissue-unspecific AP (spent hybridoma
medium, diluted in blocking solution at a final antibody concen-
tration of 1.0 to 0.5 igIml). This mixture was used to obtain a
higher apparent affinity for the antigen due to cooperative
effects.
Intestinal-type and tissue-unspecific alkaline phosphatase
estimation in urine
Urine from normal healthy volunteers was collected over a
period of 24 hours. To prevent proteolytic degradation and to
compensate for pH differences, stabilizing buffer (I MImidazole
pH 7.0, containing 2000 lU/mi aprotinine, 20 mri benzamidine,
2% Triton X-l00 and 1% NaN3) was added from the beginning
on. At the end of the collection period, stabilizing buffer was
further added to obtain a final ratio of 50 mI/liter urine. The
volume was measured and the samples were stored in liquid
nitrogen.
Intestinal-type and tissue-unspecific AP activities were mea-
sured by the EAIA-system (vide supra) and were expressed as
the total amount of enzyme excreted during the 24-hour collec-
tion period [3].
A sandwich-ELISA system was developed in order to be able
to also detect the enzymatically inactive (as well as active)
molecules of intestinal-type AP in urine samples. Microtiter
plate wells (immunplate I, Nunc, Roskilde, Denmark) were
coated for three hours at 37°C with 200 pi rabbit antiserum
against human placental AP, cross-reacting with intestinal AP
(15%; Dakopatts) diluted 1:1000 in 10 mM Tris-HCI buffer, pH
8.5, containing 10 mr'.i NaCI and 10 mrvi NaN3. The remaining
protein adsorption sites on the solid support were blocked with
250 p1 PBS containing 0.1% casein (Merck). Intestinal AP
standards or dilutions of urine samples were then added for an
overnight incubation at 4°C. Subsequently, 200 p1 of monoclo-
nal antibody "lAP 250" (spent hybridoma medium, diluted in
blocking solution to contain a final antibody concentration of
1.0 to 0.5 sg/ml) was added to the wells and the plates were
incubated for three hours at 37°C. Biotinylated rabbit anti-
mouse immunoglobulin antibodies (Dakopatts; 200 p1/well,
diluted 1:1000 with blocking solution) were added, followed by
preformed avidin-biotinylated horseradish peroxidase complex
(1:1000; Dakopatts). Peroxidase was revealed using 0.36 mr'vi
3,3' ,5,5 '-tetramethylbenzidine (Aldrich-Chemie, Steinheim,
FRG) and 0.06% H202 in 0.2 M phosphate-0. I M citrate buffer,
pH 4.3. The reaction was stopped by addition of 50 p1 2 N
H2S04 and the absorption was measured at 450 nm. After each
incubation step the wells were washed three times with PBS
containing 0.05% Tween 20.
Biochemical and immunochemical characteristics of intestinal
alkaline phosphatase from kidney tissue and urine
The following biochemical parameters of intestinal-type AP
obtained from kidney tissue were determined and were
compared with those for fetal and adult intestinal AP from
meconium and adult jejunum, respectively: inhibition by L-
phenylalanine and L-p-bromotetramisole, heat-inactivation, de-
termination of Michaelis constant (Km) for p-nitrophenylphos-
phate, electrophoretic mobility in agarose gel [17], sensitivity to
neuraminidase, and determination of the affinity constants for
the interaction between all the intestinal AP's and antibodies
"lAP 250" and "lAP 130" in an EAIA-system using a final
antibody concentration of 50 ng/ml. is defined as the molar
concentration of inhibitor resulting in a 50% inhibition of the AP
activity. The sensitivity to neuraminidase of the lower molecu-
lar weight fraction of intestinal-type AP found in urine was
determined in agarose gel electrophoresis [171 and was com-
pared with the other intestinal AP's.
Molecular weight determinations of intestinal-type AP and
tissue-unspecific AP in two kidney extracts and two urine
samples were determined with a Sephacryl S-300 gel filtration
column (97 x 2.6 cm) in 50 mt Tris-HC1 buffer, pH 7.6,
containing 0.2 M NaCI, 0.1% Triton X-lOO and 0.05% NaN3,
calibrated with ferritin (440,000 dalton), gamma-globulin
(150,000 dalton), albumin (67,000 dalton) and cytochrome C
(12,000 dalton).
Immunohistoche,nical staining for alkaline phosphalase
Monoclonal antibody "lAP 250" and monoclonal antibody
LAP 1/5 (provided by Dr. E. Bailyes) [18], specifically recog-
nizing intestinal-type AP and tissue-unspecific AP, respec-
tively, were used for the immunohistochemical localization of
these isoenzymes in histological sections of renal tissue. The
methods used have been described in detail previously for
placental AP [19]. Briefly, 1.5 mm thick slices of renal tissue,
ranging from the surface of the kidney to the papilla and cut
perpendicularly to the renal surface, were fixed for 1.5 hours in
buffered 4% formaldehyde (0.1 M sodium cacodylate buffer, pH
7.4, containing 1% CaCl2) and were embedded in low-melting-
point paraffin [20). Sections (4 tm) were mounted on poly-
L-lysine-coated slides and were treated with trypsin to render
the antigen more accessible. Binding of the monoclonal anti-
bodies was revealed by an indirect avidin-biotin-peroxidase
method, using 3-amino-9-ethyl carbazole and H202 as sub-
strate.
The sections were counterstained with methyl green and
were mounted in glycerine gelatin. Adult jejunum, processed
identically, was used as a positive control. Monoclonal anti-
body "lAP 250" was used at a concentration of 1.0 to 0.5 g/ml
(spent hybridoma medium, diluted in 10 mri Tris-HC1 pH 7.6,
containing 0.9% NaCI, 0.1% Triton X-100 and 0.004% Merthi-
olate). No placental AP could be detected in the kidney by using
the placental AP specific monoclonal antibody E6 [21].
Enzyme histochemical staining for alkaline phosphatases
Paraffin sections of human kidney adjacent to those for the
immunohistochemical staining for intestinal-type AP, were
used to localize AP by means of its enzymatic activity with
5-bromo-4-chloro-3-indoxyl-phosphate-p-toluidine salt as the
substrate and nitro blue tetrazolium as the color reagent [22].
Histochemical inhibition studies were performed as described
previously [20] by adding 1 mri L-p-bromotetramisole [23], a
specific inhibitor of liver, bone and kidney, that is, tissue-
unspecific AP, to the incubation mixture. The sections were
counterstained with methyl green and mounted in glycerine
gelatin.
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Fig. 1. Starch gel electrophoresis ofintestinal-type APfrom kidney (lanes 1, 2 and 3), adult intestinal AP (lanes 4, 5 and 6), fetal intestinal AP
(lanes 7, 8 and 9), placental AP (lanes 10, 11 and 12), and tissue-unspecjjlc APfrom kidney (lanes 13, 14 and 15) before (lanes 1, 4, 7, JO and 13)
and after incubation with an excess of the monoclonal antibodies "lAP 250" (lanes 2, 5, 8, 11 and 14) and "LAP 23#" (lanes 3, 6, 9, 12 and 15).
Table 1. Properties of intestinal and tissue-unspecific alkaline
phosphatase (AP)
Sample°
Fetal
intest.
AP
Adult
intest.
AP
Kidney
intest.
AP
Tissue
unspec.
AP
L-Phe inhibitorb mM 1.3 1.6 1.2 14.0
L-p-Bromo inhibitor" mM 1.8 1.4 1.6 0.055
HeatC % 98 87 92 17
Km lO M 0.9 0.9 0.9 0.9
Sialylation + — + ++
a Isolated as described in methods
b Molarconcentration of inhibitor resulting in a 50% inhibition of AP
activity, L-Phe: L-phenylalanine, L-p-Bromo: L-p-bromotetramisole
C Residual activity after incubation at 56°C for 15 mm
cross-reactivity with intestinal and placental AP as measured by
the EAIA.
Electrophoretic mobility
Fig. 2. Agarose gel electrophoresis (A) of fetal intestinal AP (lanes I,
2 and 3), adult intestinal AP (lanes 4, 5 and 6), intestinal-type APfrom
kidney (lanes 7, 8 and 9), and (B) of intestinal-type AP from urine
(83,000 dalton) (lanes 1, 2 and 3), tissue-unspecific AP from kidney
(lanes 4, 5 and 6) and tissue-unspec(fic APfrom urine (lanes 7, 8 and 9):
and of a reference serum sample containing intestinal AP, liver AP and
high molecular weight AP (lanes 10); before (lanes I, 4 and 7) and after
incubation with neuraminidase (lanes 2, 5 and 8), and after incubation
with an excess of monoclonal antibody "lAP 250" (lane 3, 6 and 9) (o:
origin).
Results
Monoclonal antibodies
Monoclonal antibody "lAP 250" (IgG,) raised against intes-
tinal AP showed no cross-reactivity (<0.1%, measured in the
EAIA), neither with placental AP, nor with tissue-unspecific
AP of liver, bone or kidney origin (Fig. 1). In contrast,
monoclonal anti-intestinal AP antibody "lAP 130" (IgG1)
cross-reacted with placental AP (60%) but not with tissue-
unspecific AP.
The three monoclonal anti-liver AP antibodies "LAP 23#"
(IgG1) made no distinction in reactivity with tissue-unspecific
AP of liver, bone and kidney origin and showed less than 0.1%
The electrophoretic mobility of the intestinal-type AP from
renal extracts and urines were compared in agarose gels with
fetal intestinal and adult intestinal AP mobilities (Fig. 2). Fetal
intestinal AP migrated more anodally than the adult isoenzyme.
After neuraminidase treatment its mobility was reduced, al-
though it remained still different from that of adult intestinal
AP, which was unaffected by neuraminidase treatment. Intes-
tinal-type AP isolated from kidney had a slightly less anodal
mobility than fetal intestinal AP. Intestinal-type AP found in
urine (83,000 daltons) had a more anodal mobility than intesti-
nal-type AP obtained from kidney extracts. After neuramini-
dase treatment, intestinal-type AP from renal tissue comigrated
with adult intestinal AP whereas in urine, intestinal-type AP
showed no sensitivity to neuraminidase treatment.
In the presence of antibody "lAP 250", the band of all the
intestinal AP-types was altered (Fig. 2).
Inhibition, heal-inactivation, and Km determination
The effect of various concentrations of L-phenylalanine and
L-p-bromotetramisole on the enzymatic activity of intestinal
AP isolated from meconium, adult intestine, and adult kidney
was compared. As shown in Table 1, the inhibitory effect of
L-phenylalanine and L-p-bromotetramisole on intestinal-type
AP from kidney extracts was similar to that on fetal and adult
intestinal AP.
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Table 2. Tissue content of intestinal-type and tissue-unspecific
alkaline phosphatase (AP) activity in human kidney (N = 13)
Outer
cortex
Corticomedullary
junction Inner medulla
Intest. AP 0.10 0.08 0.52 0.39 0.12 0.11
U/g SD
Tissue-unspec. AP 3.07 2.23 2.01 1.56 1.23 1.32
U/g SD
The three species of intestinal AP had an identical heat-
resistance at 56°C and an identical Km (Table 1).
Immunologic characteristics
The affinity of two monoclonal antibodies recognizing a
different epitope on intestinal AP, that is, "lAP 250" (recog-
nizing an epitope specific for intestinal AP) and "lAP 130"
(reacting with an epitope shared by placental AP) measured in
the EAIA, was similar for fetal intestinal AP, adult intestinal
AP, intestinal-type AP of renal tissue and urinary intestinal-
type AP. Langmuir plots of bound versus free fetal intestinal
AP concentrations determined by EAIA, were linear and
yielded affinity constants Ka = I x 1010 M1 and Ka = I x l0
M for antibody "lAP 250" and "lAP 130", respectively.
Intestinal and tissue-unspecific alkaline phosphatase content
of renal tissues
The amounts of intestinal-type and tissue-unspecific AP
activity present in different zones of the kidney, as determined
with the EAIA-systems, are summarized in Table 2. The
intestinal-type AP content of renal tissue taken at the junction
between cortex and medulla was significantly higher than that
found in the upper cortex and in the deeper medulla (P < 0.001,
Wilcoxon matched pairs signed rank test). The total AP activity
in the cortex, cortico-medullary junction and medulla contained
approximatively 3%, 26% and 10% intestinal-type AP, respec-
tively. No placental AP activity could be detected in either of
the zones investigated.
Histochemistry and immunohistochemistry
Positive histochemical staining for total AP was found on the
brush border of proximal tubule cells and on endothelial cells of
small blood vessels (most of the vasa rectae in the medulla,
some intertubular capillaries in the cortex, and interlobular
venules; Fig. 3B and D). In the presence of 1 mr'i L-p-
bromotetramisole, AP staining was present only on the brush
border of tubule cells in the outer stripe of the outer medulla
and in the medullary rays (Fig. 3E). In the latter, the positively
stained cells were localized in more or less straight tubule
segments oriented perpendicularly to the surface of the kidney.
In the outer stripe of the outer medulla, the cross sections of the
positive tubule segments were more circular. This pattern was
identical to the immunohistochemical pattern as obtained by the
use of monoclonal antibody "lAP 250" (Fig. 3A, C and F).
Staining for tissue-unspecific AP using monoclonal antibody
LAP 1/5 revealed that this isoenzyme is present not only in the
Sl-S2 segment, but also in the S3 segment (Fig. 4). The enzyme
was again localized exclusively on the brush border. Compari-
son of adjacent section further demonstrated that the two
isoenzymes are produced by the same S3 cells (Fig. 4A and B).
These patterns were consistently present in all biopsies inves-
tigated. No staining was obtained by using monoclonal antibody
E6, specifically recognizing placental AP in analogous histo-
chemical condition. Figure 3F shows a detail of a tubule
segment in the outer stripe of the outer medulla. Cells having
strong immunohistochemical staining for intestinal-type AP on
their brush border were present next to cells, belonging to the
same tubule section, that possessed a well-developed brush
border but that did not contain any staining for intestinal AP.
Immunostaining for intestinal-type AP on an autopsy speci-
men of a chronic hemodialysis patient's kidney revealed that
the antigen could be found in the same intact tubules.
The brush border localization of intestinal AP was confirmed
by PAS staining on an adjacent section (Fig. 5).
Urinary concentrations of intestinal-type and tissue-unspecific
alkaline phosphatase
Intestinal-type and tissue-unspecific AP activities in urine of
normal subjects (N = 5) were measured by the EAIA-system
and were expressed as the total amount of enzyme excreted
during the 24-hour collection period. Approximately 50% of the
urinary AP activity in healthy persons was of the intestinal type
(744 217 mU/24 hr). Tissue-unspecific AP activity amounted
to 624 217 mU/24 hr.
Immunoreactive intestinal AP in urine samples was deter-
mined by the sandwich-ELISA system. The immunoreactive/
enzymatically active intestinal-type AP ratio amounted to 2.1
0.5.
Molecular configuration of intestinal-type and tissue-
unspecific AP in kidney extracts and urine samples
The results achieved by gel filtration experiments on Sepha-
cryl S-300 column of a kidney extract and urine are summarized
in Table 3. In kidney extracts, the enzymatically active fraction
of intestinal-type and tissue-unspecific AP was present as
dimers (140,000 to 150,000 daltons) and polymers (450,000
daltons). In addition, a substantial fraction of intestinal-type AP
had a molecular weight that was significantly lower (83,000
daltons).
In urine, tissue-unspecific AP was present again as free
dimers and polymers whereas intestinal-type AP predominantly
occurred in its low molecular weight form.
Both in tissue extracts and urine, the immunoreactive frac-
tion of intestinal-type AP was distributed over the same molec-
ular weight species as the enzymatically active fraction.
Discussion
The predominant (80%) isoenzyme of AP in the human
kidney shares a number of properties with liver and bone AP: it
has a similar thermostability, response to amino acid inhibition,
immunological cross-reactivity, and electrophoretic mobility
after treatment with neuraminidase [24]. Therefore, the differ-
ences in electrophoretic mobility between these three forms of
tissue-unspecific AP are most likely due to post-translational
differences in glycosylation [5, 25].
However, Boyer [7] showed that human kidney AP contains
at least three electrophoretic components, one of which cross-
reacts with a polyclonal anti-intestinal AP antiserum, suggest-
ing that this component is antigenically related to the intestinal
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Fig. 3. Hjstochemical and immunohistochemkal demonstration of total and intestinal-type AP in human kidney. A. Cross-section ranging from
the renal capsule (asterisk) into the inner medulla, illustrating the distribution pattern of intestinal-type AP as obtained with monoclonal antibody
"lAP 250". MR: medullary ray. B and C. Larger magnification of adjacent sections of renal cortex showing histochemical staining for total AP (B)
in tubular cross sections and capillary endothelium, and immunostaining (C) for intestinal-type AP, only in some of the tubuli in a medullary ray.
D. Section adjacent to A, showing the histochemical staining pattern for total AP. E. Section adjacent to D, histochemically stained for AP in the
presence of 1 msi L-p-bromotetramisole. F. Immunohistochemical localization of intestinal-type AP in the corticomedullary junction, showing
positive staining predominantly on the apical surface (brush border) of isolated or clustered tubular epithelial cells, next to brush border bearing
cells that were unstained (arrow). A, D and E x 18; B and C x 110; F x 575.
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Fig. 4. Comparison between the immunohistochemical staining pat-
terns for tissue-unspecific AP (A) and intestinal-AP (B) on an adjacent
section of human kidney, obtained with monoclonal antibody LAP 1/5
and "lAP 250", respectively. A and B x 70.
enzyme. The presence of an isoenzyme similar to intestinal AP
in human kidney was subsequently confirmed by Pfleiderer et al
[10] and Alpers et at [26]. Hoffmann, Dorner and Morris [27]
demonstrated that also in equine kidney there are two electro-
phoretically distinct forms of AP, both of which, however,
behave identical to intestinal AP with respect to their reactivity
with an antiserum to intestinal AP.
The results of the present study confirm that two different
isoenzymes of AP are expressed in the human kidney. One of
them is the classical renal form of tissue-unspecific AP. All
biochemical characteristics determined indicate that the second
isoenzyme that is present in renal tissue is virtually identical to
the true intestinal isoenzyme: 1) the affinity for two monoclonal
antibodies against intestinal AP ("lAP 250", specifically recog-
nizing intestinal AP and "lAP 130", recognizing an epitope in
common placental AP) is identical. 2) The inhibition character-
istics for L-phenylalanine and L-p-bromotetramisole, are simi-
lar. 3) The binding characteristics for the dye Reactive Yellow
13 are comparable to those of adult intestinal and fetal intestinal
AP. 4) Its electrophoretic mobility is slightly less anodal than
that of fetal intestinal AP; however, after neuraminidase treat-
ment it became indistinguishable from adult intestinal AP,
Fig. 5. Comparison between the immunohistochemical staining pat-
tern for intestinal-type AP obtained with monoclona! antibody "lAP
250" (A) and the PAS-staining (B) on an adjacent section of human
kidney. A and B x 517.
Table 3. The distribution of the different fractions of intestinal-type
and tissue-unspecific alkaline phosphatase (AP) in two kidney
extracts and in two urine samples after S-300 gelfiltration
Molecular weight
dalton 83,000 141,000 151,000 450,000
Kidney extract,
Intestinal AP
- enzymatically active % 37—15 63—12 0—0 0—73
- immunoreactive % 49—30 51—8 0—0 0—62
Tissue-unspecific AP
- enzymatically active % 0—0 0—0 100—31 0—69
Urine,
Intestinal AP
- enzymatically active % 83—96 0—0 0—0 17—4
- immunoreactive % 84—93 0—0 0—0 16—7
Tissue-unspecific AP
- enzymatically active % 0—0 0—0 23—63 77—37
which contains no sialic acid at all [241. It is interesting to note
that the non-sialylated form of intestinal AP is found only in
those sites of production where the enzyme is in immediate
contact with a microbiological flora, which is a potential source
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of neuraminidase, whereas the sialylated forms are exclusively
found in a sterile environment (fetal intestine, kidney). The
observation that the mobility of fetal intestinal AP after neur-
aminidase treatment is still higher than that of adult intestinal
AP, as also reported by others [28, 29], is suggestive for
additional differences possibly at the protein level [30]. Some of
our data are in disagreement with those of Pfleiderer et al [10],
who described differences in inhibition by L-phenylalanine,
Km, and heat resistance compared to adult intestinal AP. These
differences may, however, be due to differences in sample
compositions [311.
Using immunohistochemical staining techniques based on a
monoclonal antibody specifically recognizing intestinal AP and
histochemical techniques in combination with the inhibitor
L-p-bromotetramisole, we could demonstrate that intestinal-
type AP is produced in the normal human kidney only in some
cortical and corticomedullary tubule cells displaying a distinct
brush border at the light microscopical level, indicative for their
proximal tubule nature. According to the topological distribu-
tion of these intestinal-type AP containing tubular cross sec-
tions in the kidney (medullary rays and outer stripe of outer
medulla), and because of the presence of a well-developed
brush border in these cells, it is concluded that intestinal-type
AP is produced exclusively by the S3 segment of the proximal
tubulus, as defined by Kriz and Bankir [32]. This corticomed-
ullary distribution was confirmed biochemically by the different
intestinal-type/tissue-unspecific AP ratios found for the renal
zones investigated. The enzyme was localized on the brush
border. This membranous localization in the S3 segment is in
conflict with the distal collecting duct localization described by
Alpers et al [26] and with a predominantly cytoplasmic local-
ization as described by Pfleiderer et al [10]. Their experiments
were done using a polyclonal antiserum against human and calf
intestinal AP, respectively. The cytosolic localization was even
argued by the latter using differential centrifugation techniques.
The histochemical and immunohistochemical results demon-
strate that the proximal convoluted tubulus (Sl-S2 segment)
produces exclusively tissue-unspecific AP. In addition, this
isoenzyme is coexpressed with intestinal-type AP in the same
S3 cells. Consequently, tissue-unspecific AP does not display a
segment specificity, contrary to intestinal-type AP.
Many arguments indicate that the presence of intestinal AP in
the normal human kidney is due to a local production and not to
trapping of intestinal AP circulating in the serum: I) the fact that
intestinal-type AP from the kidney tissue is sialylated in con-
trast to intestinal AP from serum; 2) its localization on the brush
border of individual tubule cells in a well-defined tubule seg-
ment; 3) the molecular weight of intestinal AP in serum (140,000
daltons, data not shown) [331 that is too high to be filtered
through the glomerulus and subsequently reabsorbed by tubule
cells.
One may speculate on the physiological reasons for the
expression of two different isoenzymes in two adjacent regions
of the tubule system of a nephron. It may constitute an
adaptation to local differences in the composition of the tubule
fluid in these two regions: there is a significant fall in pH,
bicarbonate and phosphate, and an increased ammonium con-
centration in the last segment of the proximal tubule [34].
Alternatively, their occurrence may be related to functional
differences between these proximal tubule segments. These
functional differences indeed exist; the oxidative metabolism,
Na-K ATPase activity, active sodium transport [34], and the
capacity for lysosomal proteolysis [35] are very high in the first
segment and are progressively reduced along the proximal
tubule.
The production of intestinal-type AP by the kidney inspired
certain authors [261 to hypothetize that the kidney itself might
be the source of the increased serum levels of intestinal AP that
are frequently observed in chronic dialysis patients [26, 36, 37].
However, we feel that there are certain arguments in opposition
to this statement. Indeed, there is our observation that intesti-
nal-type AP, as it occurs in renal tissue, is sialylated, in contrast
to the intestinal AP found in serum of chronic dialysis patients
and in the adult intestine. Secondly, the kidney in chronic
dialysis patients is in general sclerosed, strongly fibrotic, and
poorly vascularized [38], making the release of substantial
amounts of intestinal-type AP into the circulation highly im-
probable. Finally, the immunohistochemical distribution pat-
tern for intestinal-type AP in a chronic dialysis kidney was not
more abundant than in the normal kidney (unpublished data).
Total AP has been often analyzed in urine, in attempts to use
it as an indicator for proximal tubule injury [1, 4]. Analysis of
urine samples of healthy individuals and patients after receiving
aminoglycoside antibiotics with known tubulo-toxic side ef-
fects, revealed that intestinal-type AP constitutes a consider-
able fraction of the total AP activity in urine (50%), as was also
observed by others [10]. Significantly higher intestinal-type AP
excretion values were found in aminoglycoside treated patients
compared to healthy individuals. Since total AP measurements
in urine are hampered by the instability of one of its compo-
nents, that is, tissue-unspecific AP, it is clear that intestinal AP,
which is considerably more stable [5], might be a better marker
of nephrotoxicity. The measurement of the immunoreactive
form of intestinal-type AP (enzymatically active as well as
inactive) in urine samples also gives a more reliable value of the
enzyme concentration. Moreover, the S3 segment is of partic-
ular clinical importance, since this segment is preferentially
damaged by ischemia, heavy metals and different classes of
drugs, including cisplatin and cephalosporins [2, 39, 401. Since
intestinal-type AP is the first substance described to be exclu-
sively localized in the S3 segment of the nephron, it should be
possible to use this isoenzyme of AP as a specific marker for
this particular segment of the nephron. This is supported by the
observation of Pfleiderer et al [10] that in aminoglycoside-
treated patients the release of intestinal-type AP and tissue-
unspecific AP into urine are not correlated.
The lower molecular weight of intestinal-type AP (83,000) in
urine as compared to tissue-unspecific AP in urine is puzzling
and suggests that the release of this isoenzyme from the brush
border of the S3 cells is due to or accompanied by some kind of
yet undefined enzymatic degradation, occurring locally or in a
more distal part of the nephron. Jung and Pergande [411
reported that approximately 50% of AP and alanine aminopep-
tidase in urine are present as soluble, that is, non-particulate,
material, whereas this was only 24% for gamma-glutamyltrans-
ferase.
In conclusion, the human kidney produces two different
isoenzymes of AP: a tissue-unspecific AP and a second one that
is immunologically and biochemically almost identical to adult
intestinal AP, except for its sialylation. The latter isoenzyme is
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produced only in tubuloepithelial cells of the S3 segment of the
proximal tubule, from which it is released into urine as a lower
molecular weight form.
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